|1.||Gangoiti, Jon A: 2 articles (03/2015 - 01/2015)|
|2.||Gertsman, Ilya: 2 articles (03/2015 - 01/2015)|
|3.||Nyhan, William L: 2 articles (03/2015 - 01/2015)|
|4.||Barshop, Bruce A: 2 articles (03/2015 - 01/2015)|
|5.||Panyard-Davis, Jan: 1 article (01/2015)|
|6.||Lin, Hong-Yan: 1 article (10/2014)|
|7.||Yang, Guang-Fu: 1 article (10/2014)|
|8.||Xu, Yu-Ling: 1 article (10/2014)|
|9.||Yang, Wen-Chao: 1 article (10/2014)|
|10.||Ming, Ze-Zhong: 1 article (10/2014)|
01/01/1999 - "In the present study, 2(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), a potent inhibitor of p-hydroxyphenylpyruvate dioxygenase (which catalyzes the formation of homogentisic acid from p-hydroxyphenylpyruvic acid) was adopted as a possible therapeutic agent for alkaptonuria. "
01/01/2015 - "Nitisinone (NTBC) has been shown to effectively treat alkaptonuria by blocking the conversion of 4-hydroxyphenylpyruvate to HGA, but there have been concerns that using doses higher than about 2 mg/day could cause excessively high levels of tyrosine, resulting in crystal deposition and corneal pathology. "
10/01/2014 - "4-Hydroxyphenylpyruvate dioxygenase (HPPD), converting 4-hydroxyphenylpyruvate acid to homogentisate, is an important target for treating type I tyrosinemia and alkaptonuria due to its significant role in tyrosine catabolism. "
01/01/2014 - "p-Hydroxyphenylpyruvate, an intermediate of the Phe/Tyr catabolism, improves mitochondrial oxidative metabolism under stressing conditions and prolongs survival in rats subjected to profound hemorrhagic shock."
01/01/2014 - "The aim of this study was to test the effect of a small volume administration of p-hydroxyphenylpyruvate (pHPP) in a rat model of profound hemorrhagic shock and to assess a possible metabolic mechanism of action of the compound. "
|3.||Hepatocellular Carcinoma (Hepatoma)
01/01/1995 - "Decreased activity of 4-hydroxyphenylpyruvic acid dioxygenase in the liver of mouse strain III is associated with tyrosinemia. "
04/01/1991 - "A murine model for type III tyrosinemia: lack of immunologically detectable 4-hydroxyphenylpyruvic acid dioxygenase enzyme protein in a novel mouse strain with hypertyrosinemia."
03/01/2015 - "We studied the correlation of these indolic compounds in other disorders of tyrosine metabolism including tyrosinemia types I and II as well as transient tyrosinemia, and demonstrated that 4-hydroxyphenylpyruvate (4-HPP) was directly responsible for the promotion of this pathway. "
08/01/2007 - "Mutations in the gene for 4-hydroxyphenylpyruvic acid dioxygenase (HPD) cause either autosomal recessive tyrosinemia type III or autosomal dominant hawkinsinuria. "
11/01/2000 - "Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria."
|5.||Liver Diseases (Liver Disease)
01/01/1954 - "[Degradation of p-hydroxyphenyl-pyruvic acid in liver disease in the presence of l-ascorbic acid and other substances]."
03/07/1997 - "Isotope-dilution assays are sensitive enough to determine tyrosine, p-hydroxyphenylpyruvate and p-hydroxyphenyllactate content in normal subjects, and may be useful for studying disorders of tyrosine metabolism, including inborn errors of metabolism, liver disease and ascorbic acid deficiencies."
|4.||6- (beta- pyridyl)- 3- hydroxy- pyrazol(3,4b)pyridine
|10.||Tyrosine Transaminase (Tyrosine Aminotransferase)